AC
RVNC

Antara Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Antara Capital’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100,000
Closed -$1.52M – 304
2021
Q4 		$1.63M Buy
+100,000
New +$1.67M 0.08% 120

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Antara Capital's RVNC Position: Q1 2022 in Review

Antara Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2022, closing a stake of 100,000 shares — an estimated $1.52M sold.

Antara Capital first reported a position in RVNC in Q4 2021 and held it in 1 quarter. The position peaked at $1.63M in Q4 2021. 156 funds tracked by Wall St. Rank hold RVNC as of Q1 2022.

  • Antara Capital reported no remaining Revance Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
  • Antara Capital sold 100,000 Revance Therapeutics, Inc. shares in Q1 2022, an estimated $1.52M.
  • Antara Capital first reported a position in Revance Therapeutics, Inc. in Q4 2021 and held it in 1 quarter.
  • Antara Capital's Revance Therapeutics, Inc. position peaked at $1.63M in Q4 2021.
  • 156 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2022.

Based on Antara Capital's 13F filing for Q1 2022, filed 16 May 2022.